N/A N=281 Oral Cell DNA Adducts in Smokers
Lung Cancer
Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=16 Metabolism of NNK in Japanese Americans
Smoking
Primary: The Ratio of D4-hydroxy Acid to D4- NNAL (an Estimate if NNK Alpha Hydroxylation) — 0.133; 0.175 Ratio
N/A N=15 Assessing E-Cigarettes for Tobacco Harm Reduction in the Context of Lung Cancer Screening
Electronic Cigarette Use · Smoking, Cigarette · Nicotine Dependence
Primary: Study Feasibility — 15 Participants
Early Phase 1 N=146 Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
Lung Cancer · Tobacco Use Disorder · Breast Cancer
Primary: Feasibility of a Smoking Cessation Intervention Among Cancer Patients — 55; 33 Participants
N/A N=303 Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial
Smoking Cessation
Primary: Number of Participants With Biochemically Verified 7-day Point Prevalence Tobacco Abstinence at 6 Months — 29; 51 Participants
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=53 Motivating a Spectrum of Cancer Patients to Quit Smoking
Cancer · Smoking
Primary: Number of Participants Who Consent to Participate in the Study- Feasibility — 53 Participants
N/A N=19 Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers
Nicotine Dependence, Other Tobacco Product · Bladder Cancer · Lung Cancer
Primary: Change in Daily Cigarette Smoking Given 10 or More E-cigarette Sessions in a Day — 4.37 number of Daily Cigarettes
N/A N=520 Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens
Lung Cancer
Primary: Rate of Moderate to High Arsenic Level in Cases and Controls — 0.04; 0.04 mcg/dL
Phase 4 N=90 Tobacco Use Treatment in Cancer Patients
Smoking, Cigarette
Primary: Smoking 7-Day Point Prevalence at 12 Weeks — 2; 2; 3 Participants
Early Phase 1 N=35 Bronchoscopy in Determining the Effect of E-Cigarette Smoking on Biomarkers in the Lungs
Cigarette Smoker · Current Every Day Smoker
Primary: Changes in Cytokines — 0.2473; -0.04988; -0.1137; -0.05875 pg/ml
N/A N=169 Monitoring of Exhaled Carbon Monoxide to Promote Pre-operative Smoking Cessation
Smoking
Primary: Preoperative Carbon Monoxide Levels
N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Phase 2 N=38 Carboplatin, Pemetrexed Disodium, and Bevacizumab for Patients With Stage III or IV Non-Small Cell Lung Cancer Who Are Light/Never Smokers
Lung Cancer
Primary: Progression-free Survival — 12.6 months
Phase 3 N=207 Extended Varenicline Treatment for Smoking Among Cancer Patients
Nicotine Dependence
Primary: 7-day CO-verified Tobacco Abstinence — 28; 32; 16; 17 participants
Phase 3 N=398 Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers
Smoking · Pulmonary Disease, Chronic Obstructive · Tobacco Use Disorder
Primary: Smoking Abstinence (Point Prevalent) — 23; 24 Participants — p=0.88
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
Phase 1 N=17 Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History
Squamous Cell Carcinoma of the Head and Neck
Primary: Maximum Tolerated Dose (MTD) of Olaparib — 50 mg twice daily
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 2 N=107 Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers
Lung Cancer · Tobacco Use Disorder
Primary: Urinary Levels of Biomarkers of NNK Metabolism — 42.8; 0.36; 0.28; 49.7 pmol/mg creatinine
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
Phase 2 N=85 S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Lung Cancer
Primary: Overall Survival — 29.8 months
N/A N=944 Promoting Smoking Cessation in Lung Cancer Screening Through Proactive Treatment
Smoking Reduction · Tobacco Use · Tobacco Smoking
Primary: Self-reported Smoking Abstinence — 50; 51 Participants — p=0.83
N/A N=47 Pilot Study of Patient Navigation to Promote Smoking Cessation
Cigarette Smoking
Primary: Engagement in Smoking Cessation Treatment — 7; 9 participant
Phase 2 N=13 Sunitinib in Never-Smokers With Lung Adenocarcinoma
Lung Cancer
Primary: Objective Response Rate (ORR) — 7.69 percentage of participants
N/A N=1,094 Implementation of Smoking Cessation Within NCI Community Oncology Research Program (NCORP) Sites
Smoking Cessation
Primary: Percentage of Patients With 7-day Sustained Smoking Abstinence Reported in the Patient Survey — 13.0; 13.5 percentage of participants — p=0.865
N/A N=7,439 Follow-Up Study for Exubera
Diabetes Mellitus
Primary: Rate of Primary Lung Cancer Mortality — 0.48; 0.17 Deaths per 1000 patient years (PY)
N/A N=11 Brain Stimulation For Cancer Smokers
Cancer of Head and Neck · Breast Cancer · Prostate Cancer
Primary: The Number of Enrollment — 4; 4 participants
N/A N=200 A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung
Squamous Non-small Cell Lung Cancer
Primary: Time on Treatment With Afatinib or Chemotherapy During Second Line (2L) Treatment — 7.3; 4.2 months
Phase 2 N=130 Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Breast Cancer · Colorectal Cancer · Lung Cancer
Primary: Retention — 53.8; 67.7 percentage of participants